A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2
740
about 4.6 years
18+
13 sites in CA, CT, FL +8
About this study
Researchers are testing a treatment called HER3-DXd for people with advanced solid tumors. The trial will last about 1688 days and enroll approximately 740 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take HER3-DXd
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort)
Secondary: Correlation Between HER3 Protein Expression and Efficacy, Disease Control Rate As Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort), Duration of Response As Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort), Overall Number of Participants With Treatment-emergent Adverse Events Following HER3-DXd Monotherapy (All Cohorts), Overall Survival Following HER3-DXd Monotherapy (All Cohorts), Pharmacokinetic Parameter Area Under the Concentration Curve for HER3-DXd (All Cohorts), Pharmacokinetic Parameter Maximum Serum Concentration for HER3-DXd (All Cohorts), Pharmacokinetic Parameter Time to Maximum Serum Concentration for HER3-DXd (All Cohorts)
Oncology